# Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

> **NCT02847650** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 57 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06649751

## Key facts

- **NCT ID:** NCT02847650
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-17
- **Primary completion:** 2018-01-29
- **Final completion:** 2018-01-29
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Study B7601011 was terminated on 29 Jan 2018 due to lack of efficacy in moderate/advanced Parkinson's disease.
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02847650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02847650, "Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02847650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*